AllerGene AI Therapeutics has appointed Gad Berdugo to its Board of Directors, enhancing its strategic growth efforts following a significant investment from Explorium Capital.
On June 9, 2026, AllerGene AI Therapeutics, a company focused on pioneering in vivo targeted-lipid nanoparticle (tLNP) mRNA chimeric antigen receptor (CAR) therapies for severe allergic and mast cell-driven diseases, announced the appointment of Gad Berdugo as an independent board member. This move coincides with an investment from Explorium Capital through the Cane Angel Network, a group associated with the University of Miami.
Berdugo brings over three decades of experience in biotechnology and corporate development, having held leadership roles in notable firms such as Editas Medicine and Abbott Laboratories. His expertise in RNA-based therapeutics and lipid nanoparticle technologies aligns well with AllerGene's innovative approaches. Dr. Sid P. Kerkar, the company's CEO, expressed confidence that Berdugo's background will significantly contribute to advancing AllerGene's mRNA CAR platform.
AllerGene aims to develop therapies that specifically target mast cells to provide long-term protection against severe allergic reactions, addressing critical medical needs. Berdugo's enthusiasm for joining the board highlights the transformative potential of AllerGene's technology in improving patient outcomes for those with limited treatment options. This investment marks a pivotal moment for AllerGene as it seeks to broaden its investor base and advance its preclinical strategies.